Piramal Pharma Quarterly Results

Charts

YoY Net Sales (Quarterly)

Operating Margin

EPS Growth

POSITIVES

Revenue growth in the latest quarter shows a strong upward trend, reflecting robust demand for pharmaceuticals.
Operating margin improvement indicates better cost management and operational efficiency compared to previous quarters.
Strategic investments in R&D are beginning to yield results, fostering innovation and potential new product launches.

NEGATIVES

Declining net profit margin raises concerns about profitability and cost pressures affecting the bottom line.
Increased debt levels pose risks related to financial stability and could impact future growth opportunities.
Sales growth has slowed compared to prior quarters, indicating potential market saturation or increased competition.

Field	Mar 23	Jun 23	Sep 23	Dec 23	Mar 24	Jun 24	Sep 24	Dec 24	Mar 25	Jun 25
Revenue	2,163.58	1,748.85	1,911.38	1,958.57	2,552.36	1,951.14	2,241.75	2,204.22	2,754.07	1,933.71
Expenses	1,812.31	1,616.53	1,645.74	1,690.20	2,022.43	1,746.65	1,900.14	1,866.48	2,193.08	1,827.01
Operating Profit	351.27	132.32	265.64	268.37	529.93	204.49	341.61	337.74	560.99	106.70
Other Income	24.50	38.31	49.19	61.51	26.38	19.54	61.11	12.13	42.03	58.40
Interest	104.25	118.52	109.87	105.88	114.22	106.96	107.64	103.31	103.68	86.15
Depreciation	184.41	173.61	184.51	186.32	196.13	184.55	192.22	196.81	242.76	197.28
Profit Before Tax	94.89	-107.11	39.56	19.36	227.48	-45.08	120.12	66.80	272.80	-79.02
Tax	44.78	-8.53	34.54	9.25	126.21	43.56	97.53	63.12	119.30	2.68
Net Profit	50.11	-98.58	5.02	10.11	101.27	-88.64	22.59	3.68	153.50	-81.70
Eps in Rs	0.41	-0.81	0.04	0.08	0.77	-0.67	0.17	0.03	1.16	-0.62